Experimental Hepatitis B Drug Shows Promise for Functional Cure

Breakthrough Drug Offers Hope Against Hepatitis B

A groundbreaking experimental drug called bepirovirsen, developed by GSK and Ionis Pharmaceuticals, is showing promise in delivering what researchers call a “functional cure” for some patients with chronic hepatitis B.

In two large international studies, about 1 in 5 patients treated with bepirovirsen saw their virus reduced to levels low enough for the immune system to control without ongoing therapy. This marks a significant step forward, as current treatments only suppress the virus but rarely allow patients to stop medication safely.

Why This Matters

Chronic hepatitis B affects over 250 million people worldwide and is a leading cause of liver cancer and liver failure, killing approximately 1.1 million people annually. Existing therapies require lifelong adherence, which can be difficult for patients and costly for healthcare systems.

How Bepirovirsen Works

• Targets viral genetic material to suppress replication.
• Blocks production of the surface (S) protein, a key component of the virus.
• Stimulates the immune system to maintain control over the infection.

Clinical Trial Results

• 1,838 patients participated in the studies.
• Weekly injections were given alongside standard antiviral pills.
• In 20% of patients, the virus remained undetectable for six months after stopping all treatment — a milestone researchers call a functional cure.
• Patients with lower levels of the S protein responded more positively.

Expert Opinions

Dr. Seng Gee Lim of Singapore’s National University Health System, who co-led the studies, described the results as unprecedented. Meanwhile, Dr. Anna Lok of the University of Michigan praised the findings as a “major step” but cautioned that more research is needed to determine how long remission lasts.

Regulatory Path

The drug is currently under fast-track review by the U.S. FDA, with a decision expected in October 2026. Regulators in Japan, China, and Europe are also evaluating the therapy.

Side Effects

Reported side effects were mild, including injection-site redness and temporary increases in liver enzymes. Importantly, the trials did not include patients with cirrhosis or other complicating conditions, meaning further studies are required.

Looking Ahead

If approved, bepirovirsen could revolutionize hepatitis B treatment, offering millions of patients the chance to live free from daily medication. While not yet a universal cure, the drug represents a major leap toward ending the global burden of hepatitis B.